Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail ...

Andrew Wolf, MD, discusses the growing costs, treatment advances, and geographic disparities in multiple sclerosis care. As the costs of multiple sclerosis (MS) treatments continue to rise, it is ...

For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial intelligence ...